Biomarin Pharmaceutical Inc (BMRN): Robert Baffi , EVP, Technical Operations of Biomarin Pharmaceutical Inc sold 5,000 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $87.05 per share for a total value of $435,248.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, George Eric Davis (EVP, General Counsel) sold 14,658 shares at $85.44 per share price.On May 9, 2016, Jean Jacques Bienaime (Chief Executive Officer) sold 50,000 shares at $80.15 per share price.Also, On May 4, 2016, Jeffrey Robert Ajer (EVP, Chief Commercial Officer) sold 415 shares at $86.03 per share price.On Mar 2, 2016, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 4,623 shares at $86.12 per share price.
Shares of BioMarin Pharmaceutical (BMRN) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -2.41 points or -2.77% at $84.75 with 8,69,240 shares getting traded. Post opening the session at $86.46, the shares hit an intraday low of $83.4 and an intraday high of $87.44 and the price vacillated in this range throughout the day. The company has a market cap of $13,756,790 M and the number of outstanding shares has been calculated to be 1,62,32,20,00,000 shares. The 52-week high of BioMarin Pharmaceutical is $151.75 and the 52-week low is $62.12.
Company has been under the radar of several Street Analysts.BioMarin Pharmaceutical is Upgraded by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $110. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Mar 8, 2016.BioMarin Pharmaceutical is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 107 from a previous price target of $105 .The Rating was issued on Mar 3, 2016.BioMarin Pharmaceutical is Reiterated by Wedbush to Neutral while Lowering the Price Target of the company shares to $ 105 from a previous price target of $117 . The Rating was issued on Feb 29, 2016.BioMarin Pharmaceutical is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 125 from a previous price target of $155 . The Rating was issued on Feb 26, 2016.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).